Low androgen levels may contribute to sexual dysfunction in women after allogeneic hematopoietic cell transplantation (alloHCT). However, data on serum androgens in women after alloHCT are limited. The aim of this study was to assess androgen levels and their association with chronic GvHD (cGvHD) and glucocorticoid (GC) therapy. Included were 65 allografted women, 33 with cGvHD, and 23 of these were on GC therapy. Controls were 94 healthy, age-matched women. Supportive study groups were women after autologous HCT (autoHCT; n = 20) and non-transplanted women on GC therapy (n = 26). Compared with controls, free testosterone (free T) and dehydroepiandrosterone sulfate (DHEAS) levels were lower in both the alloHCT group and GC groups; P o 0.0001 and Po 0.05, respectively. Androgens in the autoHCT group were similar or higher than controls. In the subgroup of alloHCT patients without cGvHD, free T was similar to controls (7.2 vs 8.6 pmol/L; P = 0.42), whereas DHEAS levels was lower than controls (1.7 vs 2.5 μmol/L; P = 0.008). Compared with controls, cGvHD without GC (n = 10) was associated with lower free T and DHEAS; P = 0.004 and P = 0.0004, respectively). The lowest androgen levels were seen in women with both cGvHD and GC therapy. In conclusion, low serum androgens were associated with cGvHD and GC therapy, prompting for studies assessing a possible association between low androgens and sexual dysfunction and quality of life in allografted women.
INTRODUCTION
Allogeneic hematopoietic cell transplantation (alloHCT) is associated with a number of long-term complications, primarily chronic GvHD (cGvHD) but also endocrine dysfunction and impaired sexual life. [1] [2] [3] In females, premature ovarian failure after HCT is ascribed to cytotoxicity on the ovaries of chemotherapy and conditioning. 4 Low levels of androgens may contribute to sexual dysfunction and reduced quality of life in women. However, data on serum androgen levels in female patients after alloHCT are limited. 5, 6 Androgen production in women is ovarian and adrenal based. The androgens, in order of increasing potency, include dehydroepiandrosterone (DHEA) and its sulfate DHEAS, androstenedione and testosterone (T). The ovaries and adrenal glands contribute equally to total T and androstenedione production, whereas 490% of DHEAS originate from the adrenals. 7 Androgens are precursor hormones to estrogen and also act directly on receptors in the central nervous system, reproductive organs, liver, skin, bone, muscle and adipose tissue. 8 In plasma, T circulates bound mainly to sex hormone-binding globulin (SHBG) and albumin, leaving 1-3% of total T in free or unbound state (free T). Free T is considered the component having access to target cells resulting in androgenic effects.
Testosterone in premenopausal women is positively associated with sexual function, 9 and the highest levels are achieved in the reproductive age followed by a slow steady decline with age unrelated to menopause. 10, 11 Randomized trials indicate a positive effect of T therapy in postmenopausal women with hypoactive sexual desire disorder. 12 Owing to safety concerns and lack of convincing effect, other conditions associated with low T levels are not considered established indications for T therapy. 12 DHEA is the most abundant steroid hormone in human blood and is present in serum mainly as the sulfate (DHEAS). DHEA may exert its effect after conversion to sex steroids, including T and estradiol. Direct effects of DHEA have also been proposed. 13 Thus DHEA improves physical and psychological well-being, muscle strength and bone density and reduces body fat, while low levels correlate with increased cardiovascular disease and all-cause mortality.
14 The marked decline of DHEAS with age is independent of menopausal status. 10, 11 The first objective of this study was to assess serum androgen levels in women after alloHCT. The population-based cohort included allografted adult women after reduced or myeloablative conditioning. Healthy, age-matched women constituted the control group. Secondary objectives were to study the putative impact of conditioning intensity, ongoing cGvHD and 1 glucocorticoid (GC) therapy on androgen levels. To study these aims, two supportive study groups were identified: women after autologous HCT (autoHCT) and women on GC therapy without previous HCT (GC group).
PATIENTS AND METHODS Patients
Women after alloHCT. A total of 166 women underwent alloHCT between 1996 and September 2012 in the western region of Sweden (≈1.6 million inhabitants). Seventy-six surviving female patients in CR living in Gothenburg, Trollhättan and Borås were identified. Of these, 6 declined to participate and 5 were excluded due to mental disability (n = 1), insufficient Swedish language proficiency (n = 3) or missing data (n = 1). Thus 65 patients were enrolled to give a survey participation rate of 92%.
Conditioning was myeloablative (TBI or oral busulfan 16 mg/kg combined with cyclophosphamide 120 mg/kg or fludarabine 150-180 mg/m 2 ) or reduced (mainly oral busulfan 8 mg/kg and fludarabine 150-180 mg/m 2 ). Conditioning intensity was classified according to Bacigalupo et al. 15 All patients with an unrelated donor received pretransplant antithymocyte globulin (Thymoglubuline 6 mg/kg or ATG-Fresenius 40 mg/kg) or alemtuzumab 15 mg/m 2 (n = 3). cGvHD was categorized according to the Seattle Classification 16 by reviews of medical records.
Women after autoHCT. Thirty-five women autografted during 1996-2010 and living in Gothenburg were identified. Seven of these declined participation, three had been allografted after relapse, and five could not be contacted. Thus 20 patients were enrolled. Diagnoses were lymphoma (n = 12), myeloma (n = 7) and multiple sclerosis (n = 1). All patients were in CR or PR with no ongoing chemotherapy.
Women on GC therapy without HCT (GC group). Twenty-six women were enrolled. The indications for GC therapy were hematological diseases (n = 12), lung disease (n = 6) or rheumatic disease (n = 8).
Controls
Ninety-four healthy age-matched women agreed to participate. Eighty-one of these were health-care employees. All had intact ovaries.
Laboratory methods
Serum levels of albumin, estradiol, total and free T, DHEAS, luteinizing hormone, follicle-stimulating hormone (FSH) and SHBG were analyzed in all women. S-cortisol and S-adrenocorticotropic hormone were analyzed in the GC group, autoHCT group and in 40/65 alloHCT patients but not in controls. Hormone replacement therapy (HRT) and oral contraceptives (OCP) were interrupted 24 h before blood sampling in all groups.
Hormone analyses. All samples for hormone determination were assessed at accredited laboratories. Blood samples were obtained between 0800 and 0830 hours. After separation, sera were stored at − 20°C until analysis. Concentrations of T were determined by radioimmunoassay (RIA; Spectria; Orion Diagnostica, Espoo, Finland), as described. 17 The lower limit of detection (LoD) was 0.03 nmol/L. The total imprecision was 14% at 1 nmol/L.
Free T was calculated from T, albumin and SHBG including the association constants. 18 SHBG was determined by a chemiluminescence immunoassay (Access; Beckman Coulter Inc., Brea, CA, USA), LoD 0.33 nmol/L, imprecision o7%. Albumin and cortisol were determined by electro-chemiluminescence immunoassay (Cobas 8000, Roche diagnostics, Indianapolis, IN, USA) LoD 3 g/ L and 10 mmol/L, imprecision o4%, respectively. Serum adrenocorticotropic hormone was determined by RIA (Cisbio, Codolet, France), LoD 0.4 pmol/L, imprecision o6%. Estradiol was determined by extraction RIA (Spectria, Orion Diagnostica), as described in Ankarberg-Lindgren et al. 19 LoD was 4 pmol/L and total imprecision 25-9% in the range 10-250 pmol/L. DHEAS was determined by RIA (Coat-A-Count; Siemens, Los Angeles, CA, USA), LoD was 0.03 μmol/L, total imprecision o11%. Serum luteinizing hormone and FSH concentrations were determined using a time-resolved fluoroimmunoassay (AutoDELFIA; PerkinElmer, Wallac oy, Turku, Finland). The LoDs were 0.05 U/L, total imprecision o10% for both. The reference intervals for androgens were defined as 5th-95th percentiles of healthy controls.
Statistics
In a first step, androgen and background variables were compared between the study groups and the control group. In a second step, the effect of cGvHD and ongoing GC therapy was further studied by dividing the alloHCT group into subgroups based on cGvHD and GC therapy and comparing them internally and with the other groups. In these analyses, two alloHCT patients with GC but without cGvHD and two autografted patients with GC were not utilized (Tables 3 and 4 
and Figures 1c and d).
Median values (range) are used throughout the manuscript, and Fisher's exact test and Wilcoxon's rank-sum test were applied to compare, respectively, discrete and continuous variables. The association between age and, respectively, DHEAS and free T was analyzed by means of simple linear regression in the control group and the alloHCT group without cGvHD. The regression coefficients were compared by means of normal approximation.
Ethics
Informed written consent was obtained from all women. All blood samples were encoded to ensure anonymity and blindness to the laboratory staff. The study was approved by the Ethics Review Board of Gothenburg and conducted according to the Declaration of Helsinki.
RESULTS

Study populations
Clinical characteristics of the 205 women who participated in the study are shown in Table 1 : 65 alloHCT, 20 autoHCT, 26 on GC therapy (without previous HCT), and 94 healthy age-matched controls.
AlloHCT group. Follow-up after HCT was 55 months. There were no significant differences in age or body mass index (BMI) between allografted women and controls. cGvHD was ongoing in 33 patients (51%), and 23 were on GC therapy (oral prednisolone) at a daily dose of 7.5 mg (2.5-30). Duration of GC therapy was 29 (3-183) months with no correlation with androgen levels (data not shown). Ten patients had clinical cGVHD without systemic GC therapy. Nineteen alloHCT patients were on HRT (n = 18) or OCP (n = 1). Two patients without cGvHD were on prednisolone, 5 and 2.5 mg respectively, for rheumatic diseases.
AutoHCT group. Follow-up after HCT was 71 months. Autografted women were older (P = 0.050) and had higher BMI (P = 0.026) than controls. Eight patients were on HRT. Two Abbreviations: alloHCT = allogeneic hematopoietic cell transplantation; autoHCT = autologous hematopoietic cell transplantation; BM = bone marrow; CB = umbilical cord blood; cGvHD = chronic GvHD; GC = glucocorticoid; HRT = hormone replacement therapy. 
and one myeloma patient was on maintenance GC 4 days/month. GC group. Compared with controls, patients in the GC group were older and had higher BMI (P o 0.005 for both). Daily prednisolone dose was 5 mg (2.5-20), and one patient was on OCP. Four patients were on additionally non-steroid immunosuppressive drugs. There was no statistically significant difference in GC daily dose between the GC group and the cGvHD /GC group (P = 0.83).
Control group. Of the 94 healthy controls, FSH was available from 89 subjects: 49 women had FSH in the premenopausal range (FSHo 25) and 40 in the postmenopausal range (FSH ⩾ 25). Seven women were on HRT (n = 5) or OCP (n = 2).
Endocrine findings: study groups vs controls Table 2 and Figures 1a and b depict hormone levels of patients in the study groups and controls. All androgens analyzed-T, free T and DHEAS-were lower in the alloHCT and GC groups compared with both controls and the autoHCT group, P o 0.05 for all three androgens. In the autoHCT group, T and free T were higher, but DHEAS was similar to controls.
Median FSH levels in the study groups were higher than in controls, and values in the postmenopausal range was observed in 45% of healthy controls and in 86, 95 and 72% of alloHCT, autoHCT and GC patients, respectively. In the control group, FSH ⩾ 25 status was associated with lower DHEAS, 2.4 vs 2.8 μmol/L (P = 0.017), but similar free T, 9.1 vs 8.6 pmol/L (P = 0.85), compared with women with FSH o 25. Estradiol in transplanted patients and in the GC group was lower than controls. No differences in adrenocorticotropic hormone or cortisol were observed between alloHCT and autoHCT or GC group.
AlloHCT subgroups: impact of cGvHD and GC therapy Table 3 shows clinical features and laboratory findings in controls and in allografted women with or without cGvHD and GC therapy. Figure 1 illustrates the levels of free T (Figure 1c) and DHEAS ( Figure 1d ) in controls and alloHCT subgroups. The relationships between age and androgens for controls and no GvHD patients (n = 30) are depicted in Figure 2 .
In the alloHCT group, patients with cGvHD (n = 33), or without cGvHD (no GvHD group, n = 30), did not differ with respect to age, BMI, time since HCT, donor type, conditioning intensity or HRT (data not shown). In the no GvHD group, free T levels were similar to controls, whereas DHEAS was significantly lower. Compared with the no GvHD group, the cGvHD group had significantly lower androgen levels; free T (3.2 vs 7.2 pmol/L; P = 0.0001, DHEAS (0.5 vs 1.7 μmol/L; P o0.0001). See Figures 1c  and d .
In the cGvHD group, two subgroups were identified: 23 patients had cGvHD (limited n = 4, extensive n = 19) with systemic GC therapy, and 10 patients had cGvHD (limited n = 5; extensive n = 5) without GC. In the small group of patients with cGvHD but no GC (n = 10), free T and DHEAS were lower compared with controls (4.9 vs 8.6 pmol/L, P = 0.004, and 1.5 vs 2.5 μmol/L, P = 0.0004), respectively, but not significantly different compared with the no GvHD group; free T P = 0.068, DHEAS P = 0.18. In patients with cGvHD and GC therapy, all androgens analyzed were significantly lower compared with all the other groups.
Subnormal androgen levels in the study groups Table 4 shows the number of women with subnormal androgens in each study group and in comparisons with controls. The cutoff values for subnormal free T and DHEAS were defined as levels below the lower limit for the reference intervals, that is, free T o 2.8, DHEAS o 1.5 (or o 0.9 in women aged ⩾ 45 years). Variables associated with subnormal free T and DHEAS in the alloHCT group are listed in footnotes.
Compared with controls, subnormal DHEAS was observed more often in the whole alloHCT group (45% vs 5%, P o 0.001) and in the no GvHD group (21% vs 5%, P = 0.022). Likewise, subnormal free T was more common in the alloHCT group (29% vs 5%, Po 0.001). The percentages of patients with subnormal free T in the no GvHD group, and in the subgroup of cGvHD patients without GC, were similar to controls. In the cGvHD patients on GC Abbreviations: ACTH = adrenocorticotropic hormone; alloHCT = allogeneic hematopoietic cell transplantation; autoHCT = autologous hematopoietic cell transplantation; DHEAS = dehydroepiandrosterone sulfate; Free T = free testosterone; FSH = follicle-stimulating hormone; GC = glucocorticoid; LH = luteinizing hormone; NA = not applicable; ND = not done; SHBG = sex hormone-binding globulin. therapy, 61% had subnormal free T levels (P o 0.001) and 83% had subnormal DHEAS levels. In the GC group, subnormal free T was seen in 24% and subnormal DHEAS in 88% (P = 0.011 and P o0.001, respectively).
DISCUSSION
Our study provides data on androgen levels after alloHCT in the largest group of women studied so far. We found in our population-based cohort of allografted women significantly lower serum levels of total testosterone (T), free testosterone (free T) and DHEAS compared with healthy controls. Free T was assessed with a sensitive method, and in contrast to earlier studies, we included women after reduced intensity conditioning and beyond reproductive age. No effect of conditioning intensity (reduced intensity conditioning or myeloablative conditioning) was observed, and autografted women had even higher T/free T levels than controls. In the alloHCT subgroups, patients without cGvHD had low DHEAS levels but T and free T similar to controls. cGvHD without GC therapy was associated with significantly lower androgens compared with controls. In non-transplanted women on GC therapy, androgens were significantly lower than in controls. In cGvHD patients on systemic GC therapy, all androgens were lower compared with all the other groups. Seemingly, our data point to a reduction of DHEAS caused by alloHCT per se, whereas low free T is associated with cGvHD and in particular GC therapy. Previously, the relationship between cGvHD and gonadal function has been studied in mice. Shimoji et al. 20 reported how GvHD can induce infertility by targeting the ovarian granulosa cells. In unconditioned male mice, Wagner et al. 21 demonstrated impairment of testosterone-producing Leydig cells during local acute cGvHD.
In humans, Grigg et al. 22 reported that sperm count in longterm male survivors was lower in cGvHD patients. Hovi et al. 5 reported that, in 24 young females after TBI-based conditioning, cGvHD with GC therapy was associated with subnormal androgen Abbreviations: alloHCT = allogeneic hematopoietic cell transplantation; BMI = body mass index; cGvHD = chronic GvHD; DHEAS = dehydroepiandrosterone sulfate; Free T = free testosterone; FSH = follicle-stimulating hormone; GC = glucocorticoid; HRT = hormone replacement therapy; LH = luteinizing hormone; SHBG = sex hormone-binding globulin. found low androgens and smaller ovarian and uterine volumes after myeloablative alloHCT compared with autografted women and healthy controls.
Compared with controls, low free T was observed in women with cGvHD with or without GC therapy and in non-transplanted patients with systemic GC therapy. However, T and free T levels were not significantly reduced after autoHCT or in allografted women without cGvHD. These findings suggest a high resistance to chemotherapy in ovarian androgen-producing cells, whereas estrogen-producing granulosa cells seem irreversibly damaged causing post-transplant menopause after both alloHCT and autoHCT. In the small group of patients with cGvHD but no GC, free T was moderately reduced compared with no GvHD patients. cGvHD with GC therapy was associated with the lowest levels of T and free T, indicating a negative effect of this combination on female gonadal function.
In our control group, we observed a gradual and significant decline of DHEAS levels with age in agreement with findings in studies of healthy women. 23 In autoHCT patients, DHEAS levels were similar to controls, whereas alloHCT was strongly associated with low DHEAS levels, and also in patients with neither cGvHD nor GC. Speculatively, alloHCT, irrespective of cGvHD and GC therapy, may carry a risk of premature, biological ageing related to low DHEAS levels.
GC therapy in pharmacological doses suppresses adrenal androgen precursor synthesis, leading to decreased plasma androgens in women. 24, 25 Accordingly, in this study all androgens were significantly lower in the GC group compared with controls. Subnormal DHEAS was observed in 3 of the 10 cGvHD patients without GC (P = 0.030), whereas in cGvHD patients on GC 19 of the 23 had subnormal DHEAS (P o0.001). Inversely, 24% of patients in the GC group, and 61% of patients with both cGvHD and GC, had subnormal free T. These data suggest that both cGvHD and GC add to the risk of subnormal androgen levels in allografted women. There was a disparity regarding menopausal status, based on FSH levels, between controls and transplanted patients. FSH ⩾ 25 was observed in 45% of controls but in 86% and 95% of allografted and autografted women, respectively. However, it is unlikely that the low androgens observed in women after alloHCT could be due to menopausal status. Previous studies in healthy women have demonstrated that the physiological slow decrease of free T after the third decade of life and the more marked decrease of DHEAS are both unrelated to menopause. 10, 11 In our study, free T and DHEAS levels followed this pattern (Figure 2 ). Free T levels were similar in controls and in the no GvHD group in spite of the higher prevalence of menopause in the latter group. Normal androgen levels were seen after autoHCT. Thus, though both autoSCT and alloSCT have inflicted menopause with low estradiol and high FSH in a vast majority of HCT patients, androgens seem unrelated to menopausal status.
The relatively large number of allografted women with FSH in the premenopausal range-14% vs 5% in the autoHCT group-may be ascribed to the widespread use of HRT in the alloHCT group. AlloHCT patients with HRT were younger (38 vs 55 years; P o0.0001) than patients without HRT, whereas there were no significant differences with respect to SHBG, cGvHD, DHEAS or free T between patients with or without HRT (data not shown). Likewise, 40% of autoHCT patients with normal androgen levels were on HRT. Taken together, these data make it unlikely that HRT influenced our findings.
Our study has its strengths: we included a relatively large, unselected population with a high participation rate and used sensitive RIAs for the analyses of free T and DHEAS. By using healthy controls and two other supportive study groups, it was possible to draw conclusions on the contribution of conditioning, cGvHD and GC therapy to the low androgen levels observed. However, there are study limitations. We cannot exclude the influence of misclassifications of occurrence and grading of cGvHD, and the group of healthy women included mainly healthy professionals who possibly could differ from the patients' background population.
In conclusion, women after alloHCT with cGvHD had low androgen levels, with a strong additive effect of GC therapy. Whether low androgens in allografted women bears any association to sexual dysfunction or quality of life is presently unknown. Establishing such a relationship is a prerequisite for clinical studies of androgen substitution in women with cGvHD on or off GC therapy.
